1. Scrip
  2. >>Therapy Areas
  3. >>Respiratory

Mereo On The Move With Strong COPD Data And US Listing Plan

 
• By Kevin Grogan

The UK firm, boosted by promising data for acumapimod for acute exacerbations of COPD, is seeking to conduct an initial public offering in the US.

Businessman
America calling: The UK's Mereo is looking at a US listing • Source: Shutterstock

Mereo BioPharma Group PLC.'s model of acquiring then developing assets from big pharma looks to be paying dividends again, highlighted by impressive data on its chronic obstructive pulmonary disease (COPD) drug acumapimod, bought off Novartis AG, and plans to list in the US.

Last week, the UK company announced positive top-line results from a Phase II trial with acumapimod in acute exacerbations of COPD which showed that the p38MAP inhibitor more than halved rehospitalizations, potentially filling a gaping hole in the COPD market

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Respiratory

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

GSK Talks Up Nucala COPD Hospitalization Data In Challenge To Dupixent

 
• By Kevin Grogan

As the PDUFA date for the UK major’s IL-5 inhibitor draws close.

PureTech Weighs Up Pros And Cons Of Going Private

 
• By Kevin Grogan

The biotech has rejected a takeover bid from Nordic Capital but a sale to private equity could be a solution to the public market's continued reluctance to adequately value PureTech’s hub-and-spoke business model.

More from Therapy Areas

iTeos/GSK To Terminate Collaboration After TIGIT Trials Flop

 
• By Alaric DeArment

Belrestotug is the latest anti-TIGIT candidate to fail to meet expectations. iTeos said it will pursue strategic alternatives.

‘Market Developments’ Persuade Galapagos To Rethink Spin-Off

 
• By Andrew McConaghie

CEO Paul Stoffels exits early to be succeeded by Henry Gosebruch, who will now consider ‘all options’ for the Belgian firm as it tries to claw back investor confidence.

Strong Showing For Bayer’s Pharma Business In Uncertain Times

 
• By Kevin Grogan

As CEO Anderson backs high prices for innovative drugs in Europe